Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sushma Reddy

Endocrinology, Diabetes & Metabolism Fort Gratiot, MI Medical Doctor

NPI 1427044981 CMS profile 19526

5744 Lakeshore Rd, Fort Gratiot, MI 48059

Open in the dashboard

General payments

$67,342

93 records reported · program years 2019–2025

Research payments

$108

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$66,918 paid to institutions, not to them · program year 2025

Through program year 2025, Sushma Reddy of Fort Gratiot, MI is reported in the CMS Open Payments database as having received $67,342 across 93 general payments and $108 in research payments paid to them. Separately, studies naming them as principal investigator received $66,918 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $814 2
2024 General $5,587 5
2024 Research $108 1
2023 General $4,559 9
2022 General $20,209 22
2021 General $20,619 12
2020 General $15,154 24
2019 General $399 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sushma Reddy
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Sushma Reddy were reported at $814. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Sushma Reddy Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $399 $494 $123–$2,253 $163
2020 $15,154 $335 $85–$1,841 $114
2021 $20,619 $398 $88–$1,981 $132
2022 $20,209 $364 $88–$1,568 $149
2023 $4,559 $420 $113–$1,614 $160
2024 $5,587 $440 $121–$1,646 $164
2025 $814 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dexcom, Inc. $52,425 57 payments
  2. Novo Nordisk Inc $13,991 12 payments
  3. Abbott Laboratories $467 6 payments
  4. Tandem Diabetes Care, Inc. $209 4 payments
  5. Mannkind Corporation $97 2 payments
  6. AstraZeneca Pharmaceuticals LP $39 3 payments
  7. Medtronic MiniMed, Inc. $21 1 payment
  8. Janssen Pharmaceuticals, Inc $19 1 payment
  9. Amarin Pharma Inc. $15 1 payment
  10. Genentech USA, Inc. $12 2 payments
  11. Other $47 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,690 14 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $13,788 4 payments
  3. Consulting Fee $11,566 5 payments
  4. Travel and Lodging $5,090 17 payments
  5. Food and Beverage $2,808 52 payments
  6. Honoraria $1,400 1 payment
Products named General payments · program years 2019–2025
  1. DEXCOM G6 TRANSMITTER Endocrinology $20,540 11 payments
  2. Dexcom G6 CGM System $15,073 22 payments
  3. Dexcom G6 Transmitter Endocrinology $11,674 15 payments
  4. RYBELSUS $8,512 6 payments
  5. DEXCOM G7 GSS (161) $5,068 7 payments
  6. FreeStyle Libre 3 $215 3 payments
  7. FREESTYLE LIBRE $136 1 payment
  8. t:slim X2 Insulin Pump with Control-IQ $116 1 payment
  9. AFREZZA $97 2 payments
  10. FreeStyle Libre 2 $80 1 payment
  11. Other $472 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Dexcom, Inc. $108 1 payment

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record